Publication:
Peptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells

Simple item page
dc.contributor.authorSalas, Edison
dc.contributor.authorHernández, Andrea
dc.contributor.authorLobos-González, Lorena
dc.contributor.authorPolakovicová, Iva
dc.contributor.authorMorales, Francisco
dc.contributor.authorAraya, Eyleen
dc.contributor.authorCelis, Freddy
dc.contributor.authorRomero, Carmen
dc.contributor.authorKogan, Marcelo
dc.date.accessioned2023-04-25T17:06:08Z
dc.date.available2023-04-25T17:06:08Z
dc.date.issued2022
dc.description.abstractOne of the recent attractive therapeutic approaches for cancer treatment is restoring downregulated microRNAs. They play an essential muti-regulatory role in cellular processes such as proliferation, differentiation, survival, apoptosis, cell cycle, angiogenesis, and metastasis, among others. In this study, a gold nanoplatform (GNPF) carrying miR-145, a downregulated microRNA in many cancer types, including epithelial ovarian cancer, was designed and synthesized. For targeting purposes, the GNPF was functionalized with the FSH33 peptide, which provided selectivity for ovarian cancer, and loaded with the miR-145 to obtain the nanosystem GNPF-miR-145. The GNPF-mir-145 was selectively incorporated in A2780 and SKOV3 cells and significantly inhibited cell viability and migration and exhibited proliferative and anchor-independent growth capacities. Moreover, it diminished VEGF release and reduced the spheroid size of ovarian cancer through the damage of cell membranes, thus decreasing cell viability and possibly activating apoptosis. These results provide important advances in developing miR-based therapies using nanoparticles as selective vectors and provide approaches for in vivo evaluation.
dc.description.versionVersión Publicada
dc.identifier.citationSalas-Huenuleo E, Hernández A, Lobos-González L, Polakovičová I, Morales-Zavala F, Araya E, Celis F, Romero C, Kogan MJ. Peptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells. Pharmaceutics. 2022 Apr 28;14(5):958. doi: 10.3390/pharmaceutics14050958
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics14050958
dc.identifier.urihttps://repositorio.udd.cl/handle/11447/7377
dc.language.isoen
dc.subjectOvarian cancer
dc.subjectManoplatform
dc.subjectmicroRNA
dc.titlePeptide Targeted Gold Nanoplatform Carrying miR-145 Induces Antitumoral Effects in Ovarian Cancer Cells
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourcePharmaceutics
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1. Peptide Targeted Gold Nanoplatform Carrying miR-145.pdf
Size:
2.98 MB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.63 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services